Status:
COMPLETED
HD-Tdcs and Pharmacological Intervention For Delirium In Critical Patients With COVID-19
Lead Sponsor:
Suellen Andrade
Collaborating Sponsors:
City University of New York
Conditions:
COVID-19
Delirium
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
The goal of this clinical trial Is conducted to evaluate the efficacy and safety of active or sham HD-tDCS in combination with dexmedetomidine in patients with moderate to severe ARDS due to COVID-19 ...
Eligibility Criteria
Inclusion
- age ≥18 years,
- confirmed clinical diagnosis for SARS-CoV-2,
- delirium confirmed through the CAM-ICU-7 test, applied by trained evaluators
Exclusion
- severe psychiatric illness that is not well controlled;
- pregnancy or active lactation,
- refusal of consent
- contraindications for brain stimulation such as: aneurysm clips, pacemaker, epilepsy, dermatitis at the site of stimulation
Key Trial Info
Start Date :
April 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 30 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05963958
Start Date
April 14 2021
End Date
January 30 2023
Last Update
July 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Federal University of Paraiba
João Pessoa, Paraíba, Brazil, 51051900